Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 17,909 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Adlai Nortye Ltd | ANL | NASDAQ | Depository Receipt |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0113 | -0.33% | 3.37 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.35 | 3.21 | 3.68 | 3.37 | 3.3813 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume |
|---|---|---|---|---|
| 153 | 17,909 | 3.41 | 61,109 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:35:02 | 1 | 3.30 | USD |
Adlai Nortye Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 136.28M | 40.44M | - | 5.89M | -104.87M | -2.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Adlai Nortye
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
ANL Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Company¿s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025. |
